Shawn AllweinVice President, Biologics CMC at TevaSpeaker
Shawn earned his PhD from the University of Arizona in Synthetic Organic Chemistry which was followed by an NIH Postdoctoral Fellowship at the University of North Carolina, Chapel Hill. His initial entry into the pharmaceutical industry was within Merck’s small molecule Process Research group before moving to Cephalon and then Teva Pharmaceuticals. Prior to shifting to biologics, Shawn oversaw Teva’s small molecule process development group and internal pilot plant manufacturing of clinical supplies. During this time, he generated over 30 publications in peer reviewed journals.
As part of Teva’s focus on biologics, Shawn shifted to large molecule R&D within CMC, with a focus on clinical manufacturing. Initially overseeing continuous improvement efforts in manufacturing, Shawn’s role expanded to oversee Teva’s Biologics Manufacturing Facility for Teva’s novel biologics and biosimiliar clinical programs. In 2021, Shawn became the Vice President of Biologics CMC overseeing Drug Substance, Drug Product and Analytical Development along with Manufacturing and Operations.